Sight Sciences, Inc., (SGHT): Price and Financial Metrics
SGHT Price/Volume Stats
| Current price | $6.56 | 52-week high | $8.45 |
| Prev. close | $6.83 | 52-week low | $1.04 |
| Day low | $6.53 | Volume | 116,000 |
| Day high | $6.95 | Avg. volume | 198,909 |
| 50-day MA | $6.81 | Dividend yield | N/A |
| 200-day MA | $5.54 | Market Cap | 326.40M |
SGHT Stock Price Chart Interactive Chart >
Sight Sciences, Inc., (SGHT) Company Bio
Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Latest SGHT News From Around the Web
Below are the latest news stories about SIGHT SCIENCES INC that investors may wish to consider to help them evaluate SGHT as an investment opportunity.
Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative ContractorsDecision ensures continued access to comprehensive outflow procedure enabled by OMNI® Surgical System technology for glaucoma patientsMENLO PARK, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, supports the decision announced by five Medicare Administrative Contractors (“MACs”) to withdraw their fin |
Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye DiseaseInterventional eyelid procedures enabled by TearCare technology successfully delivered clinically and statistically significant improvements in every sign and symptom measured at every time point through six monthsMENLO PARK, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today an |
Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System TechnologyProspective, long-term trial results are consistent with the significant body of published clinical evidence demonstrating the durable safety and effectiveness of procedures enabled with the OMNI Surgical System technology MENLO PARK, Calif., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced t |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start of the trading week with a look at the biggest pre-market stock movers worth watching on Monday morning! |
Independent Chairman of Sight Sciences Picks Up 14% More StockInvestors who take an interest in Sight Sciences, Inc. ( NASDAQ:SGHT ) should definitely note that the Independent... |
SGHT Price Returns
| 1-mo | 7.89% |
| 3-mo | 2.82% |
| 6-mo | 27.63% |
| 1-year | 127.78% |
| 3-year | -72.68% |
| 5-year | N/A |
| YTD | 27.13% |
| 2023 | -57.74% |
| 2022 | -30.51% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...